The stock's rise snapped a four-day losing streak.

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be ...

Guggenheim lowered the firm’s price target on Regeneron (REGN) to $950 from $1,200 and keeps a Buy rating on the shares. The firm, which is ...

The Gillette logo will replace that of UnitedHealthcare, which became the Revolution’s first (and to date only) ...

This was the stock's second consecutive day of losses.

Super Bowl 59 is officially in the books with the Philadelphia Eagles beating the Kansas City Chiefs. Here's a look at the ...

Overall, this will be the third Super Bowl that the Bay Area has hosted. Super Bowl XIX between the San Francisco 49ers and ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, 2025. The Zacks Consensus Estimate for fourth-quarter revenues is pegged ...

Six students were announced among the top 40 finalists in the Regeneron Science Talent Search Competition. The students were chosen based on their research, leadership skills and commitment to ...

Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action: The litigation is focused on the propriety of Regeneron’s statements about its compliance with applicable rules and regulations ...